Emerging Serum, Urine, and Tissue Biomarkers in the Clinical Setting

Prostate cancer management experts share their clinical insights on selecting appropriate serum, urine, and/or tissue biomarkers, highlighting specific scenarios that warrant each type of test.

EP: 1.Overview of Prostate Cancer

EP: 2.Challenges of PSA as a Diagnostic Biomarker

EP: 3.Role of Biomarker and Genetic Testing in Prostate Cancer Diagnosis

Now Viewing

EP: 4.Emerging Serum, Urine, and Tissue Biomarkers in the Clinical Setting

EP: 5.High Risk Populations in the Development of Prostate Cancer

EP: 6.Risk Stratification in Prostate Cancer Patients

EP: 7.Challenges in Risk Assessment and Biomarkers in Treatment Recommendations

EP: 8.Influences and Challenges of Biomarkers on Treatment Selection

EP: 9.Efficacy of Biomarker Test Results

EP: 10.Biomarker Use in Patients on Active Surveillance

EP: 11.Use of Molecular Biomarkers Tests

EP: 12.Integrating Biomarker Testing Into the Patient Care Journey

EP: 13.AI and the Future of Biomarkers in Prostate Cancer

EP: 14.Current Advancements in Biomarker Research

EP: 15.Unmet Needs and Treatment Gaps in Prostate Cancer

EP: 16.Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer

EP: 17.Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing

EP: 18.Tim Richardson, MD, on genetic testing in the era of targeted therapies

EP: 19.Paul Sieber, MD, on the future of genetic testing in prostate cancer

Video content above is prompted by the following question:

• In your clinical practice, are there specific situations in which you would choose serum, urine and/or tissue biomarkers? If so, can you expand on when you might use them?

Related Videos

Related Content

Advertisement

December 20th 2024

FDA reports Urgent Field Safety Notice on mini PCNL sheath

Hannah Clarke

The alert was issued to clarify that the devices should not be used for suction and irrigation.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

December 17th 2024

Agreement reached for public reimbursement of Pluvicto in Canada

Hannah Clarke

Pluvicto was approved by Health Canada in August 2022.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

December 13th 2024

Adding CAN-2409 to radiation improves DFS in localized prostate cancer

Hannah Clarke

“If approved, this approach has the potential to transform the treatment paradigm in prostate cancer, offering patients with localized disease an effective treatment option that may reduce the risk of disease recurrence," says Glen Gejerman, MD, MBA.

December 12th 2024

Published data show noninferior treatment-free survival with HIFU vs RP

Hannah Clarke

Specifically, 90% of patients in the HIFU arm vs 86% of patients in the radical prostatectomy arm were free from subsequent definitive treatment at 30 months.

Related Content

Advertisement

December 20th 2024

FDA reports Urgent Field Safety Notice on mini PCNL sheath

Hannah Clarke

The alert was issued to clarify that the devices should not be used for suction and irrigation.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

December 17th 2024

Agreement reached for public reimbursement of Pluvicto in Canada

Hannah Clarke

Pluvicto was approved by Health Canada in August 2022.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

December 13th 2024

Adding CAN-2409 to radiation improves DFS in localized prostate cancer

Hannah Clarke

“If approved, this approach has the potential to transform the treatment paradigm in prostate cancer, offering patients with localized disease an effective treatment option that may reduce the risk of disease recurrence," says Glen Gejerman, MD, MBA.

December 12th 2024

Published data show noninferior treatment-free survival with HIFU vs RP

Hannah Clarke

Specifically, 90% of patients in the HIFU arm vs 86% of patients in the radical prostatectomy arm were free from subsequent definitive treatment at 30 months.